Abstract

In this paper, the compound ethyl 2-(5-methyl-1,2,4-triazolo[1,5-a]pyrimidin-7-yl)pent-4-enoate was synthesized and identified by FT-IR,1H and 13C NMR, UV–Vis. And single crystal x-ray diffraction. In addition, theoretical calculations including an optimized structure analysis, Hirshfeld surface analysis, High Occupied Molecular Orbital (HOMO)-Lowest Unoccupied Molecular Orbital (LUMO) analysis, UV–Vis. parameters with an IEFPCM solvent model, MEP-Molecular Electrostatic Potential and NLO-Non-Linear Optical properties and a molecular docking analysis were carried out. All theoretical computations were performed by the DFT/B3LYP functional and the 6–311++G(d,p) basis set in the ground state. The assignments of calculated infrared vibrational frequencies were performed using the VEDA4 software for the first time through the optimized structure’s chk*. and the experimental and theoretical data are in good agreement. In addition, molecular docking studies between ethyl 2-(5-methyl-1,2,4-triazolo[1,5-a]pyrimidin-7-yl)pent-4-enoateand the c-MET protein (PDB ID: 5EOB) were performed by using the AutoDock Vina program. The title molecule appears to be a good inhibitor for cancer treatment due to its binding energy and ability to adhere to the active sites of the protein.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call